Table 5.

Baseline characteristics of LyMa-101 and LyMa-ITT populations (reattribution of nonrandomized patient) before and after PSM

PopulationBefore matching (PS set)After PSM (matching set)Fisher test after PSM,
P value
NumberLyMa, n = 148 LyMa-101, n = 84R group, n = 82O group, n = 82
Sex      
Male 115 (77.7%) 61 (73%) 62 (75.6%) 59 (72%) .72 
Female 33 (22.3%) 23 (27%) 20 (24.4%) 23 (28%) 
MIPI risk group      
Low 79 (53.4%) 46 (55%) 42 (51.2%) 44 (53.7%) .93 
Intermediate 842 (28.4%) 24 (28%) 24 (29.3%) 24 (29.3%) 
High 27 (18.2%) 14 (17%) 16 (19.5%) 14 (17.1%) 
Ann Arbor stage      
II 9 (6.1%) 2 (3%) 2 (2.4%) 2 (2.4%) 
III 15 (10.1%) 6 (7%) 7 (8.5%) 6 (7.3%) 
IV 124 (83.8%) 76 (90%) 73 (89%) 74 (90.2%) 
B symptoms      
No 103 (69.6%) 68 (81%) 67 (81.7%) 66 (80.5%) 
Yes 45 (30.4%) 16 (19%) 15 (18.3%) 16 (19.5%) 
Blastoid variant      
No 129 (87.2%) 70 (83%) 70 (85.4%) 70 (85.4%) 
Yes 19 (12.8%) 14 (17%) 12 (14.6%) 12 (14.6%) 
PopulationBefore matching (PS set)After PSM (matching set)Fisher test after PSM,
P value
NumberLyMa, n = 148 LyMa-101, n = 84R group, n = 82O group, n = 82
Sex      
Male 115 (77.7%) 61 (73%) 62 (75.6%) 59 (72%) .72 
Female 33 (22.3%) 23 (27%) 20 (24.4%) 23 (28%) 
MIPI risk group      
Low 79 (53.4%) 46 (55%) 42 (51.2%) 44 (53.7%) .93 
Intermediate 842 (28.4%) 24 (28%) 24 (29.3%) 24 (29.3%) 
High 27 (18.2%) 14 (17%) 16 (19.5%) 14 (17.1%) 
Ann Arbor stage      
II 9 (6.1%) 2 (3%) 2 (2.4%) 2 (2.4%) 
III 15 (10.1%) 6 (7%) 7 (8.5%) 6 (7.3%) 
IV 124 (83.8%) 76 (90%) 73 (89%) 74 (90.2%) 
B symptoms      
No 103 (69.6%) 68 (81%) 67 (81.7%) 66 (80.5%) 
Yes 45 (30.4%) 16 (19%) 15 (18.3%) 16 (19.5%) 
Blastoid variant      
No 129 (87.2%) 70 (83%) 70 (85.4%) 70 (85.4%) 
Yes 19 (12.8%) 14 (17%) 12 (14.6%) 12 (14.6%) 

In this analysis, 148 and 84 patients in the R and O groups, respectively, were matched based on baseline characteristics, resulting in 82 patients in each group. Survival curves were drawn from inclusion. Of the 149 LyMa-ITT patients, 1 patient withdrew his consent, leading to 148 patients analyzed. Of the 86 patients included in LyMa-101, 1 withdrew his consent and 1 had missing data for matching.

Fisher test was performed between matched populations.

A total of 120 randomized and 28 nonrandomized patients.

or Create an Account

Close Modal
Close Modal